The Battle of Giants: Pharma CEOs’ Quest to Dismantle PBMs

<p>The animosity between pharmaceutical companies and PBMs runs deep, fueled by diverging interests and conflicting objectives. While PBMs are crucial in managing drug benefits and containing costs, their opaque pricing practices and market dominance have drawn the ire of pharmaceutical CEOs. By seeking to dismantle PBMs, pharmaceutical companies aim to regain control over pricing, distribution, and innovation, ultimately shaping the future landscape of the healthcare industry. As this battle rages on, only time will tell which side emerges victorious and what implications it holds for patients, payers, and the broader healthcare ecosystem.</p> <p><a href="https://richardameyer.medium.com/the-battle-of-giants-pharma-ceos-quest-to-dismantle-pbms-079ff7a5a68a"><strong>Visit Now</strong></a></p>